Global Antihemophilic Factor Drug Market Research Report 2020


This report focuses on Antihemophilic Factor Drug volume and value at global level, regional level and company level. From a global perspective, this report represents overall Antihemophilic Factor Drug market size by analyzing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan.
At company level, this report focuses on the production capacity, ex-factory price, revenue and market share for each manufacturer covered in this report.

The following manufacturers are covered:
    Bayer
    Takeda
    Novo Nordisk
    Pfizer
    Grifols
    CSL Behring
    Sanofi
    Cigna
    Octapharma
    GC Pharma
    Hualan Biological Engineering
    Shanghai RAAS blood products

Segment by Regions
    North America
    Europe
    China
    Japan

Segment by Type
    250 IU
    500 IU
    1000 IU
    1500 IU
    2000 IU
    3000 IU
    4000 IU
    Other potencies

Segment by Application
    Adult
    Pediatric
Table of Contents

1 Antihemophilic Factor Drug Market Overview
    1.1 Product Overview and Scope of Antihemophilic Factor Drug
    1.2 Antihemophilic Factor Drug Segment by Type
        1.2.1 Global Antihemophilic Factor Drug Sales Growth Rate Comparison by Type (2021-2026)
        1.2.2 250 IU
        1.2.3 500 IU
        1.2.4 1000 IU
        1.2.5 1500 IU
        1.2.6 2000 IU
        1.2.7 3000 IU
        1.2.8 4000 IU
        1.2.9 Other potencies
    1.3 Antihemophilic Factor Drug Segment by Application
        1.3.1 Antihemophilic Factor Drug Sales Comparison by Application: 2020 VS 2026
        1.3.2 Adult
        1.3.3 Pediatric
    1.4 Global Antihemophilic Factor Drug Market Size Estimates and Forecasts
        1.4.1 Global Antihemophilic Factor Drug Revenue 2015-2026
        1.4.2 Global Antihemophilic Factor Drug Sales 2015-2026
        1.4.3 Antihemophilic Factor Drug Market Size by Region: 2020 Versus 2026

2 Global Antihemophilic Factor Drug Market Competition by Manufacturers
    2.1 Global Antihemophilic Factor Drug Sales Market Share by Manufacturers (2015-2020)
    2.2 Global Antihemophilic Factor Drug Revenue Share by Manufacturers (2015-2020)
    2.3 Global Antihemophilic Factor Drug Average Price by Manufacturers (2015-2020)
    2.4 Manufacturers Antihemophilic Factor Drug Manufacturing Sites, Area Served, Product Type
    2.5 Antihemophilic Factor Drug Market Competitive Situation and Trends
        2.5.1 Antihemophilic Factor Drug Market Concentration Rate
        2.5.2 Global Top 5 and Top 10 Players Market Share by Revenue
        2.5.3 Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
    2.6 Manufacturers Mergers & Acquisitions, Expansion Plans
    2.7 Primary Interviews with Key Antihemophilic Factor Drug Players (Opinion Leaders)

3 Antihemophilic Factor Drug Retrospective Market Scenario by Region
    3.1 Global Antihemophilic Factor Drug Retrospective Market Scenario in Sales by Region: 2015-2020
    3.2 Global Antihemophilic Factor Drug Retrospective Market Scenario in Revenue by Region: 2015-2020
    3.3 North America Antihemophilic Factor Drug Market Facts & Figures by Country
        3.3.1 North America Antihemophilic Factor Drug Sales by Country
        3.3.2 North America Antihemophilic Factor Drug Sales by Country
        3.3.3 U.S.
        3.3.4 Canada
    3.4 Europe Antihemophilic Factor Drug Market Facts & Figures by Country
        3.4.1 Europe Antihemophilic Factor Drug Sales by Country
        3.4.2 Europe Antihemophilic Factor Drug Sales by Country
        3.4.3 Germany
        3.4.4 France
        3.4.5 U.K.
        3.4.6 Italy
        3.4.7 Russia
    3.5 Asia Pacific Antihemophilic Factor Drug Market Facts & Figures by Region
        3.5.1 Asia Pacific Antihemophilic Factor Drug Sales by Region
        3.5.2 Asia Pacific Antihemophilic Factor Drug Sales by Region
        3.5.3 China
        3.5.4 Japan
        3.5.5 South Korea
        3.5.6 India
        3.5.7 Australia
        3.5.8 Taiwan
        3.5.9 Indonesia
        3.5.10 Thailand
        3.5.11 Malaysia
        3.5.12 Philippines
        3.5.13 Vietnam
    3.6 Latin America Antihemophilic Factor Drug Market Facts & Figures by Country
        3.6.1 Latin America Antihemophilic Factor Drug Sales by Country
        3.6.2 Latin America Antihemophilic Factor Drug Sales by Country
        3.6.3 Mexico
        3.6.3 Brazil
        3.6.3 Argentina
    3.7 Middle East and Africa Antihemophilic Factor Drug Market Facts & Figures by Country
        3.7.1 Middle East and Africa Antihemophilic Factor Drug Sales by Country
        3.7.2 Middle East and Africa Antihemophilic Factor Drug Sales by Country
        3.7.3 Turkey
        3.7.4 Saudi Arabia
        3.7.5 U.A.E
4 Global Antihemophilic Factor Drug Historic Market Analysis by Type
    4.1 Global Antihemophilic Factor Drug Sales Market Share by Type (2015-2020)
    4.2 Global Antihemophilic Factor Drug Revenue Market Share by Type (2015-2020)
    4.3 Global Antihemophilic Factor Drug Price Market Share by Type (2015-2020)
    4.4 Global Antihemophilic Factor Drug Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End

5 Global Antihemophilic Factor Drug Historic Market Analysis by Application
    5.1 Global Antihemophilic Factor Drug Sales Market Share by Application (2015-2020)
    5.2 Global Antihemophilic Factor Drug Revenue Market Share by Application (2015-2020)
    5.3 Global Antihemophilic Factor Drug Price by Application (2015-2020)

6 Company Profiles and Key Figures in Antihemophilic Factor Drug Business
    6.1 Bayer
        6.1.1 Corporation Information
        6.1.2 Bayer Description, Business Overview and Total Revenue
        6.1.3 Bayer Antihemophilic Factor Drug Sales, Revenue and Gross Margin (2015-2020)
        6.1.4 Bayer Products Offered
        6.1.5 Bayer Recent Development
    6.2 Takeda
        6.2.1 Takeda Antihemophilic Factor Drug Production Sites and Area Served
        6.2.2 Takeda Description, Business Overview and Total Revenue
        6.2.3 Takeda Antihemophilic Factor Drug Sales, Revenue and Gross Margin (2015-2020)
        6.2.4 Takeda Products Offered
        6.2.5 Takeda Recent Development
    6.3 Novo Nordisk
        6.3.1 Novo Nordisk Antihemophilic Factor Drug Production Sites and Area Served
        6.3.2 Novo Nordisk Description, Business Overview and Total Revenue
        6.3.3 Novo Nordisk Antihemophilic Factor Drug Sales, Revenue and Gross Margin (2015-2020)
        6.3.4 Novo Nordisk Products Offered
        6.3.5 Novo Nordisk Recent Development
    6.4 Pfizer
        6.4.1 Pfizer Antihemophilic Factor Drug Production Sites and Area Served
        6.4.2 Pfizer Description, Business Overview and Total Revenue
        6.4.3 Pfizer Antihemophilic Factor Drug Sales, Revenue and Gross Margin (2015-2020)
        6.4.4 Pfizer Products Offered
        6.4.5 Pfizer Recent Development
    6.5 Grifols
        6.5.1 Grifols Antihemophilic Factor Drug Production Sites and Area Served
        6.5.2 Grifols Description, Business Overview and Total Revenue
        6.5.3 Grifols Antihemophilic Factor Drug Sales, Revenue and Gross Margin (2015-2020)
        6.5.4 Grifols Products Offered
        6.5.5 Grifols Recent Development
    6.6 CSL Behring
        6.6.1 CSL Behring Antihemophilic Factor Drug Production Sites and Area Served
        6.6.2 CSL Behring Description, Business Overview and Total Revenue
        6.6.3 CSL Behring Antihemophilic Factor Drug Sales, Revenue and Gross Margin (2015-2020)
        6.6.4 CSL Behring Products Offered
        6.6.5 CSL Behring Recent Development
    6.7 Sanofi
        6.6.1 Sanofi Antihemophilic Factor Drug Production Sites and Area Served
        6.6.2 Sanofi Description, Business Overview and Total Revenue
        6.6.3 Sanofi Antihemophilic Factor Drug Sales, Revenue and Gross Margin (2015-2020)
        6.4.4 Sanofi Products Offered
        6.7.5 Sanofi Recent Development
    6.8 Cigna
        6.8.1 Cigna Antihemophilic Factor Drug Production Sites and Area Served
        6.8.2 Cigna Description, Business Overview and Total Revenue
        6.8.3 Cigna Antihemophilic Factor Drug Sales, Revenue and Gross Margin (2015-2020)
        6.8.4 Cigna Products Offered
        6.8.5 Cigna Recent Development
    6.9 Octapharma
        6.9.1 Octapharma Antihemophilic Factor Drug Production Sites and Area Served
        6.9.2 Octapharma Description, Business Overview and Total Revenue
        6.9.3 Octapharma Antihemophilic Factor Drug Sales, Revenue and Gross Margin (2015-2020)
        6.9.4 Octapharma Products Offered
        6.9.5 Octapharma Recent Development
    6.10 GC Pharma
        6.10.1 GC Pharma Antihemophilic Factor Drug Production Sites and Area Served
        6.10.2 GC Pharma Description, Business Overview and Total Revenue
        6.10.3 GC Pharma Antihemophilic Factor Drug Sales, Revenue and Gross Margin (2015-2020)
        6.10.4 GC Pharma Products Offered
        6.10.5 GC Pharma Recent Development
    6.11 Hualan Biological Engineering
        6.11.1 Hualan Biological Engineering Antihemophilic Factor Drug Production Sites and Area Served
        6.11.2 Hualan Biological Engineering Antihemophilic Factor Drug Description, Business Overview and Total Revenue
        6.11.3 Hualan Biological Engineering Antihemophilic Factor Drug Sales, Revenue and Gross Margin (2015-2020)
        6.11.4 Hualan Biological Engineering Products Offered
        6.11.5 Hualan Biological Engineering Recent Development
    6.12 Shanghai RAAS blood products
        6.12.1 Shanghai RAAS blood products Antihemophilic Factor Drug Production Sites and Area Served
        6.12.2 Shanghai RAAS blood products Antihemophilic Factor Drug Description, Business Overview and Total Revenue
        6.12.3 Shanghai RAAS blood products Antihemophilic Factor Drug Sales, Revenue and Gross Margin (2015-2020)
        6.12.4 Shanghai RAAS blood products Products Offered
        6.12.5 Shanghai RAAS blood products Recent Development

7 Antihemophilic Factor Drug Manufacturing Cost Analysis
    7.1 Antihemophilic Factor Drug Key Raw Materials Analysis
       7.1.1 Key Raw Materials
       7.1.2 Key Raw Materials Price Trend
       7.1.3 Key Suppliers of Raw Materials
    7.2 Proportion of Manufacturing Cost Structure
    7.3 Manufacturing Process Analysis of Antihemophilic Factor Drug
    7.4 Antihemophilic Factor Drug Industrial Chain Analysis

8 Marketing Channel, Distributors and Customers
    8.1 Marketing Channel
    8.2 Antihemophilic Factor Drug Distributors List
    8.3 Antihemophilic Factor Drug Customers

9 Market Dynamics
    9.1 Market Trends
    9.2 Opportunities and Drivers
    9.3 Challenges
    9.4 Porter's Five Forces Analysis

10 Global Market Forecast
    10.1 Global Antihemophilic Factor Drug Market Estimates and Projections by Type
        10.1.1 Global Forecasted Sales of Antihemophilic Factor Drug by Type (2021-2026)
        10.1.2 Global Forecasted Revenue of Antihemophilic Factor Drug by Type (2021-2026)
    10.2 Antihemophilic Factor Drug Market Estimates and Projections by Application
        10.2.1 Global Forecasted Sales of Antihemophilic Factor Drug by Application (2021-2026)
        10.2.2 Global Forecasted Revenue of Antihemophilic Factor Drug by Application (2021-2026)
    10.3 Antihemophilic Factor Drug Market Estimates and Projections by Region
        10.3.1 Global Forecasted Sales of Antihemophilic Factor Drug by Region (2021-2026)
        10.3.2 Global Forecasted Revenue of Antihemophilic Factor Drug by Region (2021-2026)
    10.4 North America Antihemophilic Factor Drug Estimates and Projections (2021-2026)
    10.5 Europe Antihemophilic Factor Drug Estimates and Projections (2021-2026)
    10.6 Asia Pacific Antihemophilic Factor Drug Estimates and Projections (2021-2026)
    10.7 Latin America Antihemophilic Factor Drug Estimates and Projections (2021-2026)
    10.8 Middle East and Africa Antihemophilic Factor Drug Estimates and Projections (2021-2026)
11 Research Finding and Conclusion

12 Methodology and Data Source
    12.1 Methodology/Research Approach
        12.1.1 Research Programs/Design
        12.1.2 Market Size Estimation
        12.1.3 Market Breakdown and Data Triangulation
    12.2 Data Source
        12.2.1 Secondary Sources
        12.2.2 Primary Sources
    12.3 Author List
    12.4 Disclaimer

List of Tables Table 1. Global Antihemophilic Factor Drug Sales (K MT) Growth Rate Comparison by Type (2015-2026) Table 2. Global Antihemophilic Factor Drug Sales (K MT) Comparison by Application: 2020 VS 2026 Table 3. Global Antihemophilic Factor Drug Market Size by Type (K MT) (US$ Million) (2020 VS 2026) Table 4. Global Key Antihemophilic Factor Drug Manufacturers Covered in This Study Table 5. Global Antihemophilic Factor Drug Sales (K MT) by Manufacturers (2015-2020) Table 6. Global Antihemophilic Factor Drug Sales Share by Manufacturers (2015-2020) Table 7. Global Antihemophilic Factor Drug Revenue (Million USD) by Manufacturers (2015-2020) Table 8. Global Antihemophilic Factor Drug Revenue Share by Manufacturers (2015-2020) Table 9. Global Market Antihemophilic Factor Drug Average Price (USD/MT) of Key Manufacturers (2015-2020) Table 10. Manufacturers Antihemophilic Factor Drug Sales Sites and Area Served Table 11. Manufacturers Antihemophilic Factor Drug Product Types Table 12. Global Antihemophilic Factor Drug Manufacturers Market Concentration Ratio (CR5 and HHI) Table 13. Global Antihemophilic Factor Drug by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Antihemophilic Factor Drug as of 2019) Table 14. Manufacturers Mergers & Acquisitions, Expansion Plans Table 15. Main Points Interviewed from Key Antihemophilic Factor Drug Players Table 16. Global Antihemophilic Factor Drug Sales (K MT) by Region (2015-2020) Table 17. Global Antihemophilic Factor Drug Sales Market Share by Region (2015-2020) Table 18. Global Antihemophilic Factor Drug Revenue (Million US$) by Region (2015-2020) Table 19. Global Antihemophilic Factor Drug Revenue Market Share by Region (2015-2020) Table 20. North America Antihemophilic Factor Drug Sales by Country (2015-2020) (K MT) Table 21. North America Antihemophilic Factor Drug Sales Market Share by Country (2015-2020) Table 22. North America Antihemophilic Factor Drug Revenue by Country (2015-2020) (US$ Million) Table 23. North America Antihemophilic Factor Drug Revenue Market Share by Country (2015-2020) Table 24. Europe Antihemophilic Factor Drug Sales by Country (2015-2020) (K MT) Table 25. Europe Antihemophilic Factor Drug Sales Market Share by Country (2015-2020) Table 26. Europe Antihemophilic Factor Drug Revenue by Country (2015-2020) (US$ Million) Table 27. Europe Antihemophilic Factor Drug Revenue Market Share by Country (2015-2020) Table 28. Asia Pacific Antihemophilic Factor Drug Sales by Region (2015-2020) (K MT) Table 29. Asia Pacific Antihemophilic Factor Drug Sales Market Share by Region (2015-2020) Table 30. Asia Pacific Antihemophilic Factor Drug Revenue by Region (2015-2020) (US$ Million) Table 31. Asia Pacific Antihemophilic Factor Drug Revenue Market Share by Region (2015-2020) Table 32. Latin America Antihemophilic Factor Drug Sales by Country (2015-2020) (K MT) Table 33. Latin America Antihemophilic Factor Drug Sales Market Share by Country (2015-2020) Table 34. Latin America Antihemophilic Factor Drug Revenue by Country (2015-2020) (US$ Million) Table 35. Latin America Antihemophilic Factor Drug Revenue Market Share by Country (2015-2020) Table 36. Middle East and Africa Antihemophilic Factor Drug Sales by Country (2015-2020) (K MT) Table 37. Middle East and Africa Antihemophilic Factor Drug Sales Market Share by Country (2015-2020) Table 38. Middle East and Africa Antihemophilic Factor Drug Revenue by Country (2015-2020) (US$ Million) Table 39. Middle East and Africa Antihemophilic Factor Drug Revenue Market Share by Country (2015-2020) Table 40. Global Antihemophilic Factor Drug Sales (K MT) by Type (2015-2020) Table 41. Global Antihemophilic Factor Drug Sales Share by Type (2015-2020) Table 42. Global Antihemophilic Factor Drug Revenue (Million US$) by Type (2015-2020) Table 43. Global Antihemophilic Factor Drug Revenue Share by Type (2015-2020) Table 44. Global Antihemophilic Factor Drug Price (USD/MT) by Type (2015-2020) Table 45. Global Antihemophilic Factor Drug Sales (K MT) by Application (2015-2020) Table 46. Global Antihemophilic Factor Drug Sales Market Share by Application (2015-2020) Table 47. Global Antihemophilic Factor Drug Sales Growth Rate by Application (2015-2020) Table 48. Bayer Antihemophilic Factor Drug Corporation Information Table 49. Bayer Description and Business Overview Table 50. Bayer Antihemophilic Factor Drug Sales (K MT), Revenue (Million US$), Price (USD/MT) and Gross Margin (2015-2020) Table 51. Bayer Main Product Table 52. Bayer Recent Development Table 53. Takeda Antihemophilic Factor Drug Corporation Information Table 54. Takeda Corporation Information Table 55. Takeda Antihemophilic Factor Drug Sales (K MT), Revenue (Million US$), Price (USD/MT) and Gross Margin (2015-2020) Table 56. Takeda Main Product Table 57. Takeda Recent Development Table 58. Novo Nordisk Antihemophilic Factor Drug Corporation Information Table 59. Novo Nordisk Corporation Information Table 60. Novo Nordisk Antihemophilic Factor Drug Sales (K MT), Revenue (Million US$), Price (USD/MT) and Gross Margin (2015-2020) Table 61. Novo Nordisk Main Product Table 62. Novo Nordisk Recent Development Table 63. Pfizer Antihemophilic Factor Drug Corporation Information Table 64. Pfizer Corporation Information Table 65. Pfizer Antihemophilic Factor Drug Sales (K MT), Revenue (Million US$), Price (USD/MT) and Gross Margin (2015-2020) Table 66. Pfizer Main Product Table 67. Pfizer Recent Development Table 68. Grifols Antihemophilic Factor Drug Corporation Information Table 69. Grifols Corporation Information Table 70. Grifols Antihemophilic Factor Drug Sales (K MT), Revenue (Million US$), Price (USD/MT) and Gross Margin (2015-2020) Table 71. Grifols Main Product Table 72. Grifols Recent Development Table 73. CSL Behring Antihemophilic Factor Drug Corporation Information Table 74. CSL Behring Corporation Information Table 75. CSL Behring Antihemophilic Factor Drug Sales (K MT), Revenue (Million US$), Price (USD/MT) and Gross Margin (2015-2020) Table 76. CSL Behring Main Product Table 77. CSL Behring Recent Development Table 78. Sanofi Antihemophilic Factor Drug Corporation Information Table 79. Sanofi Corporation Information Table 80. Sanofi Antihemophilic Factor Drug Sales (K MT), Revenue (Million US$), Price (USD/MT) and Gross Margin (2015-2020) Table 81. Sanofi Main Product Table 82. Sanofi Recent Development Table 83. Cigna Antihemophilic Factor Drug Corporation Information Table 84. Cigna Corporation Information Table 85. Cigna Antihemophilic Factor Drug Sales (K MT), Revenue (Million US$), Price (USD/MT) and Gross Margin (2015-2020) Table 86. Cigna Main Product Table 87. Cigna Recent Development Table 88. Octapharma Antihemophilic Factor Drug Corporation Information Table 89. Octapharma Corporation Information Table 90. Octapharma Antihemophilic Factor Drug Sales (K MT), Revenue (Million US$), Price (USD/MT) and Gross Margin (2015-2020) Table 91. Octapharma Main Product Table 92. Octapharma Recent Development Table 93. GC Pharma Antihemophilic Factor Drug Corporation Information Table 94. GC Pharma Corporation Information Table 95. GC Pharma Antihemophilic Factor Drug Sales (K MT), Revenue (Million US$), Price (USD/MT) and Gross Margin (2015-2020) Table 96. GC Pharma Main Product Table 97. GC Pharma Recent Development Table 98. Hualan Biological Engineering Antihemophilic Factor Drug Corporation Information Table 99. Hualan Biological Engineering Corporation Information Table 100. Hualan Biological Engineering Antihemophilic Factor Drug Sales (K MT), Revenue (Million US$), Price (USD/MT) and Gross Margin (2015-2020) Table 101. Hualan Biological Engineering Main Product Table 102. Hualan Biological Engineering Recent Development Table 103. Shanghai RAAS blood products Antihemophilic Factor Drug Corporation Information Table 104. Shanghai RAAS blood products Corporation Information Table 105. Shanghai RAAS blood products Antihemophilic Factor Drug Sales (K MT), Revenue (Million US$), Price (USD/MT) and Gross Margin (2015-2020) Table 106. Shanghai RAAS blood products Main Product Table 107. Shanghai RAAS blood products Recent Development Table 108. Sales Base and Market Concentration Rate of Raw Material Table 109. Key Suppliers of Raw Materials Table 110. Antihemophilic Factor Drug Distributors List Table 111. Antihemophilic Factor Drug Customers List Table 112. Market Key Trends Table 113. Key Opportunities and Drivers: Impact Analysis (2021-2026) Table 114. Key Challenges Table 115. Global Antihemophilic Factor Drug Sales (K MT) Forecast by Type (2021-2026) Table 116. Global Antihemophilic Factor Drug Sales Market Share Forecast by Type (2021-2026) Table 117. Global Antihemophilic Factor Drug Revenue (Million US$) Forecast by Type (2021-2026) Table 118. Global Antihemophilic Factor Drug Revenue (Million US$) Market Share Forecast by Type (2021-2026) Table 119. Global Antihemophilic Factor Drug Sales (K MT) Forecast by Application (2021-2026) Table 120. Global Antihemophilic Factor Drug Revenue (Million US$) Forecast by Application (2021-2026) Table 121. Global Antihemophilic Factor Drug Sales (K MT) Forecast by Region (2021-2026) Table 122. Global Antihemophilic Factor Drug Sales Market Share Forecast by Region (2021-2026) Table 123. Global Antihemophilic Factor Drug Revenue Forecast by Region (2021-2026) (US$ Million) Table 124. Global Antihemophilic Factor Drug Revenue Market Share Forecast by Region (2021-2026) Table 125. Research Programs/Design for This Report Table 126. Key Data Information from Secondary Sources Table 127. Key Data Information from Primary Sources List of Figures Figure 1. Picture of Antihemophilic Factor Drug Figure 2. Global Antihemophilic Factor Drug Sales Market Share by Type: 2020 VS 2026 Figure 3. 250 IU Product Picture Figure 4. 500 IU Product Picture Figure 5. 1000 IU Product Picture Figure 6. 1500 IU Product Picture Figure 7. 2000 IU Product Picture Figure 8. 3000 IU Product Picture Figure 9. 4000 IU Product Picture Figure 10. Other potencies Product Picture Figure 11. Global Antihemophilic Factor Drug Consumption Market Share by Application: 2020 VS 2026 Figure 12. Adult Figure 13. Pediatric Figure 14. Global Antihemophilic Factor Drug Market Size 2015-2026 (US$ Million) Figure 15. Global Antihemophilic Factor Drug Sales Capacity (K MT) (2015-2026) Figure 16. Global Antihemophilic Factor Drug Market Size Market Share by Region: 2020 Versus 2026 Figure 17. Antihemophilic Factor Drug Sales Share by Manufacturers in 2020 Figure 18. Global Antihemophilic Factor Drug Revenue Share by Manufacturers in 2019 Figure 19. The Global 5 and 10 Largest Players: Market Share by Antihemophilic Factor Drug Revenue in 2019 Figure 20. Antihemophilic Factor Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019 Figure 21. Global Antihemophilic Factor Drug Sales Market Share by Region (2015-2020) Figure 22. Global Antihemophilic Factor Drug Sales Market Share by Region in 2019 Figure 23. Global Antihemophilic Factor Drug Revenue Market Share by Region (2015-2020) Figure 24. Global Antihemophilic Factor Drug Revenue Market Share by Region in 2019 Figure 25. North America Antihemophilic Factor Drug Sales Market Share by Country in 2019 Figure 26. North America Antihemophilic Factor Drug Revenue Market Share by Country in 2019 Figure 27. U.S. Antihemophilic Factor Drug Sales Growth Rate (2015-2020) (K MT) Figure 28. U.S. Antihemophilic Factor Drug Revenue Growth Rate (2015-2020) (US$ Million) Figure 29. Canada Antihemophilic Factor Drug Sales Growth Rate (2015-2020) (K MT) Figure 30. Canada Antihemophilic Factor Drug Revenue Growth Rate (2015-2020) (US$ Million) Figure 31. Europe Antihemophilic Factor Drug Sales Market Share by Country in 2019 Figure 32. Europe Antihemophilic Factor Drug Revenue Market Share by Country in 2019 Figure 33. Germany Antihemophilic Factor Drug Sales Growth Rate (2015-2020) (K MT) Figure 34. Germany Antihemophilic Factor Drug Revenue Growth Rate (2015-2020) (US$ Million) Figure 35. France Antihemophilic Factor Drug Sales Growth Rate (2015-2020) (K MT) Figure 36. France Antihemophilic Factor Drug Revenue Growth Rate (2015-2020) (US$ Million) Figure 37. U.K. Antihemophilic Factor Drug Sales Growth Rate (2015-2020) (K MT) Figure 38. U.K. Antihemophilic Factor Drug Revenue Growth Rate (2015-2020) (US$ Million) Figure 39. Italy Antihemophilic Factor Drug Sales Growth Rate (2015-2020) (K MT) Figure 40. Italy Antihemophilic Factor Drug Revenue Growth Rate (2015-2020) (US$ Million) Figure 41. Russia Antihemophilic Factor Drug Sales Growth Rate (2015-2020) (K MT) Figure 42. Russia Antihemophilic Factor Drug Revenue Growth Rate (2015-2020) (US$ Million) Figure 43. Asia Pacific Antihemophilic Factor Drug Sales Market Share by Region in 2019 Figure 44. Asia Pacific Antihemophilic Factor Drug Revenue Market Share by Region in 2019 Figure 45. China Antihemophilic Factor Drug Sales Growth Rate (2015-2020) (K MT) Figure 46. China Antihemophilic Factor Drug Revenue Growth Rate (2015-2020) (US$ Million) Figure 47. Japan Antihemophilic Factor Drug Sales Growth Rate (2015-2020) (K MT) Figure 48. Japan Antihemophilic Factor Drug Revenue Growth Rate (2015-2020) (US$ Million) Figure 49. South Korea Antihemophilic Factor Drug Sales Growth Rate (2015-2020) (K MT) Figure 50. South Korea Antihemophilic Factor Drug Revenue Growth Rate (2015-2020) (US$ Million) Figure 51. India Antihemophilic Factor Drug Sales Growth Rate (2015-2020) (K MT) Figure 52. India Antihemophilic Factor Drug Revenue Growth Rate (2015-2020) (US$ Million) Figure 53. Australia Antihemophilic Factor Drug Sales Growth Rate (2015-2020) (K MT) Figure 54. Australia Antihemophilic Factor Drug Revenue Growth Rate (2015-2020) (US$ Million) Figure 55. Taiwan Antihemophilic Factor Drug Sales Growth Rate (2015-2020) (K MT) Figure 56. Taiwan Antihemophilic Factor Drug Revenue Growth Rate (2015-2020) (US$ Million) Figure 57. Indonesia Antihemophilic Factor Drug Sales Growth Rate (2015-2020) (K MT) Figure 58. Indonesia Antihemophilic Factor Drug Revenue Growth Rate (2015-2020) (US$ Million) Figure 59. Thailand Antihemophilic Factor Drug Sales Growth Rate (2015-2020) (K MT) Figure 60. Thailand Antihemophilic Factor Drug Revenue Growth Rate (2015-2020) (US$ Million) Figure 61. Malaysia Antihemophilic Factor Drug Sales Growth Rate (2015-2020) (K MT) Figure 62. Malaysia Antihemophilic Factor Drug Revenue Growth Rate (2015-2020) (US$ Million) Figure 63. Philippines Antihemophilic Factor Drug Sales Growth Rate (2015-2020) (K MT) Figure 64. Philippines Antihemophilic Factor Drug Revenue Growth Rate (2015-2020) (US$ Million) Figure 65. Vietnam Antihemophilic Factor Drug Sales Growth Rate (2015-2020) (K MT) Figure 66. Vietnam Antihemophilic Factor Drug Revenue Growth Rate (2015-2020) (US$ Million) Figure 67. Latin America Antihemophilic Factor Drug Sales Market Share by Country in 2019 Figure 68. Latin America Antihemophilic Factor Drug Revenue Market Share by Country in 2019 Figure 69. Mexico Antihemophilic Factor Drug Sales Growth Rate (2015-2020) (K MT) Figure 70. Mexico Antihemophilic Factor Drug Revenue Growth Rate (2015-2020) (US$ Million) Figure 71. Brazil Antihemophilic Factor Drug Sales Growth Rate (2015-2020) (K MT) Figure 72. Brazil Antihemophilic Factor Drug Revenue Growth Rate (2015-2020) (US$ Million) Figure 73. Argentina Antihemophilic Factor Drug Sales Growth Rate (2015-2020) (K MT) Figure 74. Argentina Antihemophilic Factor Drug Revenue Growth Rate (2015-2020) (US$ Million) Figure 75. Middle East and Africa Antihemophilic Factor Drug Sales Market Share by Country in 2019 Figure 76. Middle East and Africa Antihemophilic Factor Drug Revenue Market Share by Country in 2019 Figure 77. Turkey Antihemophilic Factor Drug Sales Growth Rate (2015-2020) (K MT) Figure 78. Turkey Antihemophilic Factor Drug Revenue Growth Rate (2015-2020) (US$ Million) Figure 79. Saudi Arabia Antihemophilic Factor Drug Sales Growth Rate (2015-2020) (K MT) Figure 80. Saudi Arabia Antihemophilic Factor Drug Revenue Growth Rate (2015-2020) (US$ Million) Figure 81. U.A.E Antihemophilic Factor Drug Sales Growth Rate (2015-2020) (K MT) Figure 82. U.A.E Antihemophilic Factor Drug Revenue Growth Rate (2015-2020) (US$ Million) Figure 83. Sales Market Share of Antihemophilic Factor Drug by Type (2015-2020) Figure 84. Sales Market Share of Antihemophilic Factor Drug by Type in 2019 Figure 85. Revenue Share of Antihemophilic Factor Drug by Type (2015-2020) Figure 86. Revenue Market Share of Antihemophilic Factor Drug by Type in 2019 Figure 87. Global Antihemophilic Factor Drug Sales Growth by Type (2015-2020) (K MT) Figure 88. Global Antihemophilic Factor Drug Sales Market Share by Application (2015-2020) Figure 89. Global Antihemophilic Factor Drug Sales Market Share by Application in 2019 Figure 90. Global Revenue Share of Antihemophilic Factor Drug by Application (2015-2020) Figure 91. Global Revenue Share of Antihemophilic Factor Drug by Application in 2020 Figure 92. Bayer Total Revenue (US$ Million): 2019 Compared with 2018 Figure 93. Takeda Total Revenue (US$ Million): 2019 Compared with 2018 Figure 94. Novo Nordisk Total Revenue (US$ Million): 2019 Compared with 2018 Figure 95. Pfizer Total Revenue (US$ Million): 2019 Compared with 2018 Figure 96. Grifols Total Revenue (US$ Million): 2019 Compared with 2018 Figure 97. CSL Behring Total Revenue (US$ Million): 2019 Compared with 2018 Figure 98. Sanofi Total Revenue (US$ Million): 2019 Compared with 2018 Figure 99. Cigna Total Revenue (US$ Million): 2019 Compared with 2018 Figure 100. Octapharma Total Revenue (US$ Million): 2019 Compared with 2018 Figure 101. GC Pharma Total Revenue (US$ Million): 2019 Compared with 2018 Figure 102. Hualan Biological Engineering Total Revenue (US$ Million): 2019 Compared with 2018 Figure 103. Shanghai RAAS blood products Total Revenue (US$ Million): 2019 Compared with 2018 Figure 104. Price Trend of Key Raw Materials Figure 105. Manufacturing Cost Structure of Antihemophilic Factor Drug Figure 106. Manufacturing Process Analysis of Antihemophilic Factor Drug Figure 107. Antihemophilic Factor Drug Industrial Chain Analysis Figure 108. Channels of Distribution Figure 109. Distributors Profiles Figure 110. Porter's Five Forces Analysis Figure 111. North America Antihemophilic Factor Drug Sales (K MT) and Growth Rate Forecast (2021-2026) Figure 112. North America Antihemophilic Factor Drug Revenue (Million US$) and Growth Rate Forecast (2021-2026) Figure 113. Europe Antihemophilic Factor Drug Sales (K MT) and Growth Rate Forecast (2021-2026) Figure 114. Europe Antihemophilic Factor Drug Revenue (Million US$) and Growth Rate Forecast (2021-2026) Figure 115. Latin America Antihemophilic Factor Drug Sales (K MT) and Growth Rate Forecast (2021-2026) Figure 116. Latin America Antihemophilic Factor Drug Revenue (Million US$) and Growth Rate Forecast (2021-2026) Figure 117. Middle East and Africa Antihemophilic Factor Drug Sales (K MT) and Growth Rate Forecast (2021-2026) Figure 118. Middle East and Africa Antihemophilic Factor Drug Revenue (Million US$) and Growth Rate Forecast (2021-2026) Figure 119. Asia Pacific Antihemophilic Factor Drug Sales (K MT) and Growth Rate Forecast (2021-2026) Figure 120. Asia Pacific Antihemophilic Factor Drug Revenue (Million US$) and Growth Rate Forecast (2021-2026) Figure 121. Bottom-up and Top-down Approaches for This Report Figure 122. Data Triangulation Figure 123. Key Executives Interviewed

This research study involved the extensive usage of both primary and secondary data sources.  The research process involved the study of various factors affecting the industry, including the government policy, market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry, and market risks, opportunities, market barriers and challenges. Top-down and bottom-up approaches are used to validate the global market size market and estimate the market size for manufacturers, regions segments, product segments and applications (end users). All possible factors that influence the markets included in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data. The market size for top-level markets and sub-segments is normalized, and the effect of inflation, economic downturns, and regulatory & policy changes or other factors are not accounted for in the market forecast. This data is combined and added with detailed inputs and analysis from QYResearch and presented in this report.
 

After complete market engineering with calculations for market statistics; market size estimations; market forecasting; market breakdown; and data triangulation, extensive primary research was conducted to gather information and verify and validate the critical numbers arrived at. In the complete market engineering process, both top-down and bottom-up approaches were extensively used, along with several data triangulation methods, to perform market estimation and market forecasting for the overall market segments and sub segments listed in this report. Extensive qualitative and further quantitative analysis is also done from all the numbers arrived at in the complete market engineering process to list key information throughout the report.
 

Secondary Sources occupies Approximately 25% of Sources, such as press releases, annual reports, Non-Profit organizations, industry associations, governmental agencies and customs data, and so on; This research study involved the usage of widespread secondary sources; directories; databases such as Bloomberg Business, Wind Info, Hoovers, Factiva (Dow Jones & Company), TRADING ECONOMICS, and avention; Investing News Network; statista; Federal Reserve Economic Data; annual reports; BIS Statistics; ICIS; company house documents; CAS(American Chemical Society); investor presentations; and SEC filings of companies. Secondary research was used to identify and collect information useful for the extensive, technical, market-oriented, and commercial study of the Light Aircraft market. It was also used to obtain important information about the top players, market classification and segmentation according to industry trends to the bottom-most level, and key developments related to market and technology perspectives.
 

In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side include product manufacturers (and their competitors), opinion leaders, industry experts, research institutions, distributors, dealer and traders, as well as the raw materials suppliers and producers etc.
 

The primary sources from the demand side include industry experts such as business leaders, marketing and sales directors, technology and innovation directors, supply chain executive, end users (product buyers), and related key executives from various key companies and organizations operating in the global market.
 

Primary research was conducted to identify segmentation types, product price range, product applications, key players, raw materials supply and the downstream demand, industry status and outlook, and key market dynamics such as risks, influence factors, opportunities, market barriers, industry trends, and key player strategies.
 

New Pharmaceuticals and Healthcare Reports

Other Reports by QY Research

Global Vinyl Versatate Market Professional Survey Report 2020

The global Vinyl Versatate market was valued at US$ 328.37 million in 2019 and will reach US$ 639.42 million by the end of 2026, growing at a CAGR of 9.75% during 2021-2026. This report focuses on Vinyl Versatate volume and value at the global level,...

Global Refrigerated Containers Market Report, History and Forecast 2015-2026

Market Analysis and Insights: Global Refrigerated Containers Market In 2019, the global Refrigerated Containers market size was US$ 1376.17 million and it is expected to reach US$ 1973.42 million by the end of 2026, with a CAGR of 5.52% between 2020 ...

Global Medium-density Fiberboard Market Research Report 2020

Market Analysis and Insights: Global Medium-density Fiberboard Market The global Medium-density Fiberboard market is valued at US$ 28473.08 million in 2019 and is expected to reach US$ 41016.95 million by the end of 2027, growing at a CAGR of 4.59% d...

Global Low Voltage DC Circuit Breaker Market Professional Survey Report 2020

The global Low Voltage DC Circuit Breaker market was valued at 1237.26 million US$ in 2019 and will reach 1816.27 million US$ by the end of 2026, growing at a CAGR of 5.65% during 2020-2026. This report focuses on Low Voltage DC Circuit Breaker volum...

Global Glass Nonwovens Wet-Laid Industry Research Report Growth Trends and Competitive Analysis 2020-2026

Market Overview The Glass Nonwovens Wet-Laid market was valued at US$ 1246 million in 2019 and is projected to reach US$ 1605 million by 2026, at a CAGR of 3.68% during the forecast period. In this study, 2018 has been considered as the base year and...

Publisher: QY Research